Vimta Labs Limited (VIMTALABS) — Board Meeting | 20 July 2026

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board approved unaudited Q1 FY26 financial results
💡 Investor Takeaway
The company delivered strong quarterly growth with approved results and no material accounting issues.

The board approved unaudited Q1 FY26 results showing revenue of ₹1,128.86 crores, profit of [amount context mismatch] crores, and EPS of [amount context mismatch], reflecting growth from prior quarters. The results were reviewed by the Audit Committee and statutory auditor, with no material misstatements noted. The company highlighted its PPP agreement for a National Food Testing Laboratory and employee stock option grants.

📄 View Original Announcement (PDF)

About Vimta Labs Limited (VIMTALABS)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹2,878.27 Cr P/E: 23.3 ROE: 19.2% ROCE: 24.3% Div Yield: 0.31%

View full VIMTALABS stock details →

📡 Get AI alerts when VIMTALABS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track VIMTALABS — Free

📊 More VIMTALABS filings

See all VIMTALABS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when VIMTALABS files new disclosures

Track VIMTALABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIMTALABS — Free

Free account · 2 AI queries/day